Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Theravance Inc (THRX)    
$35.41 0.63 (1.75%) as of 4:30 Mon 6/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 84,767,000 as of 6/30
Market Cap: 3.00(B)
Last Volume: 707,307 Avg Vol: 620,126
52 Week Range: $18.67 - $41.87
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Biotechnology

Member Indexes:
      

Rankings:
     
Insider 3 Months    : 41.2
Insider 6 Months    : 41.4
Insider 3/6 Months : 83.1
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. Co. is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system / pain. Co.'s key programs include: RELOVAIR™, Long-Acting Muscarinic Antagonist / Long-Acting Beta2 Agonist ('719/vilanterol) and Bifunctional Muscarinic Antagonist-Beta2 Agonist, each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist program.
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 193,563 310,090 906,772 11,156,117
Total Buy Value $2,147,483,647 $2,147,483,647 $2,147,483,647 $2,147,483,647
Total People Bought 1 1 1 1
Total Buy Transactions 1 2 4 8
Total Shares Sold 517,619 524,619 844,450 907,329
Total Sell Value $17,619,342 $17,774,322 $26,540,481 $27,901,436
Total People Sold 5 5 5 6
Total Sell Transactions 8 9 17 22
End Date 2013-03-17 2012-12-14 2012-06-15 2011-06-16

   
Records found: 380
  Page 1 of 16  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-06-07 4 S $35.04 $1,087,572 D/D (31,038) 303,416 -1%     
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-29 4 AS $35.01 $133,318 D/D (3,808) 48,749 2%     
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-05-29 4 OE $3.10 $94,159 D/D 11,021 213,705     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-05-20 4 D $37.01 $371,802 D/D (10,046) 711,505     -
   Shafer Bradford J Sr VP, Gen. Counsel, Secretary   •       –      –    2013-05-20 4 D $37.01 $121,837 D/D (3,292) 334,454     -
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-05-20 4 D $37.01 $121,837 D/D (3,292) 202,684     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-05-20 4 D $37.01 $169,136 D/D (4,570) 137,916     -
   Blum Leonard M Sr VP, Chief Comm. Officer   •       –      –    2013-05-20 4 D $37.01 $121,837 D/D (3,292) 286,094     -
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-20 4 D $37.01 $90,415 D/D (2,443) 52,557     -
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-13 4 AS $40.33 $650,483 D/D (16,129) 55,000 -13%     
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-13 4 OE $34.00 $548,386 D/D 16,129 71,129     -
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-03 4 OE $29.65 $478,225 D/D 16,129 71,129     -
   Brinkley David L Head of Business Dev.   •       –      –    2013-05-03 4 AS $34.77 $560,805 D/D (16,129) 55,000 6%     
   Glaxosmithkline Plc 10% Owner   –       –       •   2013-04-30 4 B $6,699,220.00 $2,147,483,647 I/I 193,563 26,721,193 1.5 7%     
   Winningham Rick E Chief Executive Officer   •       •      –    2013-04-30 4 OE $9.69 $3,731,247 D/D 385,161 977,083     -
   Winningham Rick E Chief Executive Officer   •       •      –    2013-04-30 4 AS $33.64 $8,597,169 D/D (255,532) 721,551 7%     
   Brinkley David L Head of Business Dev.   •       –      –    2013-04-30 4 OE $6.15 $51,248 D/D 8,333 72,104     -
   Brinkley David L Head of Business Dev.   •       –      –    2013-04-30 4 AS $33.76 $577,490 D/D (17,104) 55,000 7%     
   Mammen Mathai SVP, Research & Early Clin Dev   •       –      –    2013-04-30 4 AS $33.72 $236,164 D/D (7,000) 205,976 7%     
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-04-30 4 OE $17.91 $3,060,443 D/D 170,879 313,365     -
   Aguiar Michael W Sr VP, Chief Financial Officer   •       –      –    2013-04-30 4 AS $33.77 $5,776,341 D/D (170,879) 142,486 7%     
   Waltrip William H Director   –       •      –    2013-04-24 4 A $0.00 $0 D/D 6,000 68,258     -
   Levine Arnold J Director   –       •      –    2013-04-24 4 A $0.00 $0 D/D 6,000 85,988     -
   Fore Henrietta Director   –       •      –    2013-04-24 4 A $0.00 $0 D/D 6,000 27,000     -
   Whitesides George M Director   –       •      –    2013-04-24 4 A $0.00 $0 D/D 6,000 574,571     -
  380 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 16
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2010 J3SG.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us